Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.
about
Maintenance therapies for multiple myelomaAn inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cellsSalvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.Bortezomib in multiple myeloma: systematic review and clinical considerations.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Evolution of treatment regimens in multiple myeloma: a social network analysisThe 26S proteasome complex: an attractive target for cancer therapyNeutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy.Ubiquitination: Added complexity in Ras and Rho family GTPase function.Postrelapse survival rate correlates with first-line treatment strategy with thalidomide in patients with newly diagnosed multiple myeloma: a meta-analysis.Boron as a platform for new drug design.Bortezomib for the treatment of previously untreated multiple myeloma.First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany.A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation.Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis.Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos.Boronate-mediated biologic delivery.'Borono-lectin' based engineering as a versatile platform for biomedical applications.Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched studyAn overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation
P2860
Q24198800-38D4E9C3-356C-4768-A7C5-F4693CE3E8AEQ28486021-E7813FA7-C43E-4E29-9B3F-B4F3B4A6A53BQ33414239-7FB8F258-FCD3-469A-A801-08C440F2B106Q33982728-1ED66602-9CF5-4468-823B-7D3193FCD461Q34253548-254279AD-0085-46AA-967F-41910852DA27Q35224015-038D5493-6ABD-4326-AEA1-940A5987FAAFQ35624079-3F1FD076-42CA-4392-B5C5-1BFF76BF34FEQ36416269-624949A8-B059-495C-A9EC-BEAD6711A1E8Q36562341-8A6562EA-643E-46CB-A4D5-E5BF988A11D7Q37656305-F5FDF644-6A8D-4F79-9033-0A6D4D0F1B94Q37965170-1F871F88-C004-46D2-8B0F-761AC5B8A40FQ37970604-C1833F87-DF92-4216-810D-CDAF16ED6083Q38040432-F682CFC1-42B9-4008-B61F-D745FCFE5DCAQ38096055-C2B91FE1-7E98-4C37-B225-7F5E307A8A87Q38670350-0FE3A5EE-D1AE-49BD-9CAE-D1C0DE719365Q38819936-F912E20A-B2C7-43B3-92C1-029F64CC09C7Q39208231-F983DF16-3B29-4475-836B-68CBB91EDF37Q39449414-BD3E5056-6392-4150-BD69-019286AE96B5Q41859282-6A39E28B-77AC-439C-9D58-6CE9E2293BEBQ47131624-DCB1B311-0EB5-4F61-81F6-C0E6EFCCA71BQ57903951-0E03F726-9F58-4168-8EAE-0C69DCDB71CDQ57904533-B62FC800-FDF2-4C2C-9691-19FD9180EF49
P2860
Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Thalidomide versus bortezomib ...... myeloma: a systematic review.
@en
Thalidomide versus bortezomib ...... myeloma: a systematic review.
@nl
type
label
Thalidomide versus bortezomib ...... myeloma: a systematic review.
@en
Thalidomide versus bortezomib ...... myeloma: a systematic review.
@nl
prefLabel
Thalidomide versus bortezomib ...... myeloma: a systematic review.
@en
Thalidomide versus bortezomib ...... myeloma: a systematic review.
@nl
P2860
P31
P356
P1476
Thalidomide versus bortezomib ...... myeloma: a systematic review.
@en
P2093
Ambuj Kumar
Keath Wheatley
P2860
P356
10.1002/AJH.21904
P577
2011-01-01T00:00:00Z